Neuphoria Therapeutics Inc. Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes
Neuphoria Therapeutics Inc. (NEUP) reported Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes of -AUD 15.31 million for the 12-month period ending 2023-06-30, per its 20-F filed 2023-10-18.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges · last filed 2023-10-18
| Period end | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 12 month |
|---|---|
| 2023-06-30 | -15.31M AUD 20-F · filed 2023-10-18 |
| 2022-06-30 | 5.86M AUD 20-F · filed 2023-10-18 |
| 2021-06-30 | 23.93M AUD 20-F · filed 2023-10-18 |
| 2020-06-30 | -9.46M AUD 20-F · filed 2022-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |